Viskase Holdings, Inc. (VISK): Operating Income
-$5.31M
Year ended 2025-12-31
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$5.31M | n/m | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | -$1.33M | n/m | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | -$1.04M | n/m | 2025-02-21, From 2023-01-01 |
| 2022-12-31 | -$1.03M | n/m | 2024-03-20, From 2022-01-01 |
| 2021-12-31 | -$469.0K | n/m | 2023-02-16, From 2021-01-01 |
| 2020-12-31 | -$1.30M | n/m | 2022-02-25, From 2020-01-01 |
| 2019-12-31 | -$973.0K | n/a | 2021-02-23, From 2019-01-01 |
| No annual figure between 2015-12-31 and 2019-12-31. | |||
| 2015-12-31 | $10.80M | -62.5% | 2016-03-21, From 2015-01-01 |
| 2014-12-31 | $28.79M | +58.5% | 2016-03-21, From 2014-01-01 |
| 2013-12-31 | $18.16M | n/m | 2015-03-05, From 2013-01-01 |
| 2012-12-31 | -$3.97M | n/m | 2014-03-14, From 2012-01-01 |
| 2011-12-31 | -$16.45M | n/m | 2014-03-14, From 2011-01-01 |
| 2010-12-31 | -$575.0K | n/m | 2013-03-18, From 2010-01-01 |
| 2009-12-31 | -$57.09M | n/a | 2012-03-12, From 2009-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Viskase Holdings, Inc. (VISK) | 2025-12-31 | -$5.31M | n/m |
| Ocugen, Inc. (OCGN) | 2025-12-31 | -$62.92M | n/m |
| PharmaCyte Biotech, Inc. (PMCB) | 2026-04-30 | -$6.85M | n/m |
| Cognition Therapeutics Inc (CGTX) | 2025-12-31 | -$47.80M | n/m |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | -$68.78M | n/m |
| Jasper Therapeutics, Inc. (JSPR) | 2025-12-31 | -$83.88M | n/m |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | -$47.38M | n/m |
| IN8BIO, Inc. (INAB) | 2025-12-31 | -$19.44M | n/m |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | -$121.24M | n/m |
Compare VISK, OCGN, PMCB, CGTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗